Table 2.
Characteristics of patients with esophageal squamous cell carcinoma treated with Ad.CMV‐p5330
| Patient no. | Age & gender | Time to tumor progressiona | Site of p53 mutation | Viral particles | Treatment cycles | Tumor size (mm)c | Local & overall responsed | Prognosis after gene therapye |
|---|---|---|---|---|---|---|---|---|
| 1 | 64M | 7M | Exon 5 | 15 × 1011 | 2 | 43 | SD & SD | 19M dead |
| 2 | 71M | 7M | Exon 7 | 10 × 1011 | 5 | 25 | SD & SD | 15M dead |
| 3 | 62M | 5M | Negativeb | 15 × 1011 | 3 | 50 | SD & PD | 3M dead |
| 4 | 78M | 2M | Exon 8 | 10 × 1011 | 2 | 30 | PD & PD | 6M dead |
| 5 | 66M | 2M | Exon 7 | 10 × 1011 | 3 | 40 | SD & SD | 63M alive |
| 6 | 60M | 1M | Exon 7 | 20 × 1011 | 1 | 70 | SD & PD | 2M dead |
| 7 | 67F | 4F | Exon 5 | 10 × 1011 | 2 | 38 | SD & SD | 13M dead |
| 8 | 58M | 8M | Exon 6 | 10 × 1011 | 2 | 40 | SD & SD | 15M dead |
| 9 | 48M | 2M | Exon 7 | 25 × 1011 | 4 | 100 | SD & SD | 12M dead |
| 10 | 77M | 12M | Negativeb | 20 × 1011 | 2 | 68 | SD & PD | 2M dead |
a
Time to tumor progression after completion of chemoradiation therapy (M, months).
b
No mutation among exons 5, 6, 7 and 8.
c
Tumor size is sum of esophageal tumor and lymph node.
d
Treatment response was determined 4 wks after completion of therapy by external review board.
e
Survival months after first injection of Ad.CMV‐p53 (M, months).
Shimada et al.30
PD, progressive disease; SD, stable disease.